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An average of 3.35 years follow-up was used. IMSS population with hypertension was 
estimated using the national prevalence of 30.8% (20 years and older) reported by 
the National Health Survey of 2006, the proportion (70%) of the Mexican population 
over 20 years old reported by the National Population Council and the number of 
total IMSS afﬁ liates. a 5% discount rate was applied to costs. Results are presented 
in US dollars (exchange rate 13 MXN/dollar). RESULTS: Primary hypertension 
annual treatment cost per patient including related cardiovascular events was $556.56 
for patients treated with candesartan/HCT and $718.42 with losartan/HCT treatment. 
Theoretical savings yield by candesartan/HCT are $161.86 per patient. Calculated 
hypertension patients afﬁ liated to the IMSS was 10 million. Average annual savings 
given this population are $1.707 million for the institution with 1.8 million bed days, 
4.4 million physician visits and 5.3 million laboratory tests avoided. CONCLUSIONS: 
This analysis showed that the reduction of cardiovascular events with the use of 
candesartan/HCT for treating primary hypertension could save $1.707 million to the 
IMSS.
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OBJECTIVES: To evaluate the costs of ambrisentan within therapeutic health 
program in 2nd phase line treatment of adult patients with idiopathic, familiar or 
associated with connective tissue disease pulmonary hypertension of III NYHA stage. 
METHODS: The analysis compared two scenarios: existing and new. The existing 
one assumed application of bosentan, iloprost, treprostinil or sildenaﬁ l in patients with 
pulmonary hypertension of III NYHA stage in case of 1st line treatment with bosentan 
or sildenaﬁ l failure. The new one included also administration of ambrisentan. Popula-
tion’s abundance and market shares of drugs used in presented indication were esti-
mated on the basis of PHPOL Registry. Cost data were collected from public payer’s 
perspective (National Health Fund) in Poland and calculated in ﬁ ve years horizon. 
Ofﬁ cial ex factore price of Volibris® was provided by the producer. Cost analysis was 
performed under assumption that ambrisentan would be ﬁ nanced within the frame-
work of Catalogue of active substances used in therapeutic health programs. a range 
of variables was checked in a sensitivity analysis. RESULTS: Introduction of ambris-
entan to Catalogue of active substances used in therapeutic health programs and 
administration in 2nd line treatment of adult patients with idiopathic, familiar or 
associated with connective tissue disease pulmonary hypertension of III NYHA stage 
brought savings from public payer’s perspective amounted to: 178,782PLN 
(64,719PLN–342,497PLN) in ﬁ rst year, 385,054PLN (132,673PLN–769,277PLN) in 
second year, 614,006PLN (203,224PLN–1,266,372PLN) in third year, 646,137PLN 
(206,854PLN–1 366,336PLN) in fourth year and 674,573PLN (210,053PLN–
1,455,310PLN) in ﬁ fth following year. CONCLUSIONS: Treatment with ambrisentan 
leads to savings from public payer’s perspective and constitutes substantial therapeutic 
achievement (it is administered orally and only once a day unlike other drugs currently 
used in presented indication).
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OBJECTIVES: The purpose of this study was to perform comparative pharmacoeco-
nomic analysis of antithrombotic therapy with rivaroxaban (Xarelto®) and enoxapa-
rin (Clexane®) in the conditions of real clinical practice of total hip (THR) and knee 
(TKR) replacement. METHODS: The method of budget impact modeling was used. 
RESULTS: At equal duration of venous thromboembolism (VTE) prophylaxis at THR 
(35 days) rivaroxaban turned out to be more budget saving than enoxaparin by 2399 
RUB (62.71c), reducing the quantity of complications cases (pulmonary embolism, 
deep venous thrombosis, death) by 26 cases per one thousand patients. At various 
duration of prophylaxis at THR—rivaroxaban (35 days) and enoxaparin (14 days)—
rivaroxaban application has also demonstrated budget savings by 100 RUB(2.63c) 
thus reducing the quantity of complications by 74 cases per one thousand patients. 
The results of comparison of two weeks VTE prophylaxis after TKR have shown the 
most sizeable economy after rivaroxaban application by 7734 RUB(202.164c) and 
simultaneous complications decrease by 92 cases per one thousand patients. CON-
CLUSIONS: Rivaroxaban demonstrated budget savings compared to enoxaparin at 
all prophylaxis regiments at THR and TKR by reducing thrombosis complications.
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OBJECTIVES: AF is a big problem of the Russian Health Care System because cardio-
vascular diseases are the leaders in the structure of morbidity and mortality. Systemic 
statistics of AF and AF BI are unknown. Aim: To calculate the AF BI based on regional 
data and extrapolate the received data for Russia. METHODS: Evaluation of AF 
incidence and prevalence in dynamic (1995–2005) in the North-West region of Russia, 
calculation of direct and indirect costs and perspective modeling. RESULTS: As 
estimation—AF prevalence in Russia is 3.2/1000, incidence is 1,766/100,000, parox-
ysmal and persistent AF are increased from 0.6 to 1.8 and 0.25 to 0.6/1,000 accord-
ingly. Hypertension (73%), ischemic hart disease (65.2%), diabetes (9%) occurred in 
the ﬁ rst episode of AF. Hospitalization rate is increased by 66%, estimated rate is 
1.23 mln. pts./year, and it’s length is 6.9 days on the average, AF lethality is 1%. 
Disability rate is 40%, estimated amount of disability days is 3.3 mln/year. Calculated 
hospitalization cost for one year is 11.35 bln RUR (~c298 mln), cost for out-patients’ 
day-service—29.6 mln RUR (~c778 ths) and cost of out-patient treatment for all 
patients is no less than 32.5 bln RUR (c855 mln) including drugs cost—19.6 bln RUR 
(Euro). Estimated surgery cost is 260 mln RUR (c6.8 mln). Undirected adjusted cost 
is no less than 3 bln RUR (~c80 mln). CONCLUSIONS: AF BI in the Russian Federa-
tion leads to the biggest governmental, insurance and personal expenditures as com-
pared to the developed countries. Annual BI AF without deﬁ ciancial GDP per person 
is no less than c5.5 ths. Decreasing of AF BI can be particularly achieved in case of a 
better pharmaceutical control of AF aimed at saving budget charges due to the less 
hospitalization and surgeon rates.
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OBJECTIVES: The majority of cardiac device recipients are routinely followed. 
Implantable Cardioverter Deﬁ brillators (ICDs) devices must be systematically and 
continually monitored, with follow-up frequency adjusted for the patient’s underlying 
medical condition, device-related issues, and patient preferences. In México, in CMN-
IMSS La Raza, the current implant rate for ICD is 5 per million (equating to 30 new 
implants per year) and every year an average of 180 patients implanted with ICD are 
attending follow-up visits at La Raza hospital in Mexico. This simulation provides 
evidence to support the use of remote follow up and monitoring of ICDs via the 
CareLink Network as an alternative to follow-up consultations in attending an out-
patient clinic setting. METHODS: The simulation considers patients implanted with 
ICD (without CareLink) will on average require 4 in-clinic follow-up consultations 
per year whilst those with CareLink will only require 1 in-clinic follow-up consultation 
(4–6 weeks post implant) and 3 remote follow-up consultations. Reviewing patient 
data provided via the CareLink Network (remote monitoring consultation) requires 
an average 8.4 minutes of cardiac physiologist time compared to 25.8 minutes for an 
in–clinic follow-up consultation. RESULTS: For each patient per year the introduction 
of a remote monitor to support device follow-ups, lead to a reduction in cardiac 
physiologist time of 52.2 minutes equivalent to $17,970 MXP ($30,686 MXP without 
CareLink versus $12,716 MXP on CareLink). The cost of a cardiac physiologist time 
is $2630.00 MXP (per hour) equating to MXP 368.20 per remote follow-up versus 
$1130.90 MXP per in-clinic follow-up. CONCLUSIONS: The use of CareLink can 
potentially generate economic beneﬁ ts for the health professional, institution, health 
system and the patient.
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OBJECTIVES: To develop a model to assess the clinical and economic impact of a 
pocket-sized ultrasound (PSU) versus standard ultrasound for abdominal aortic aneu-
rysm (AAA) screening in Italy. METHODS: The model was developed from the 
perspective of the Servizio Sanitario Nazionale, the national health care system in Italy, 
during an 8-year time horizon for 65–74-year-old males who had smoked in their 
lifetime. Our model assumed 100% of eligible males could be screened with the PSU, 
as compared to 29% actually screened with standard ultrasound, and that screening 
with a PSU would incur no additional cost. Model inputs were derived from major 
clinical trials (4-year rates of mortality, aortic rupture, and elective and emergency 
surgeries) and DRG reimbursement rates (costs). Model outputs of number of deaths, 
ruptures and costs (2010 euros) were calculated. One-way sensitivity analyses were 
conducted. RESULTS: A PSU strategy yielded a 33.8% (0.32% vs. 0.48%) and 46.6% 
